Skip to main content

Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs have been used or studied for several urologic indications: stress urinary incontinence (SUI) — the most-studied, with duloxetine approved for SUI in Europe but not the US; post-prostatectomy incontinence (PPUI); mixed urinary incontinence; overactive bladder; chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS); chronic pelvic pain in women; and premature ejaculation. Duloxetine is the dominant SNRI in urology — venlafaxine and milnacipran / levomilnacipran have limited direct urologic evidence and distinct safety constraints. SNRIs also produce clinically important urologic adverse effects — urinary hesitation / retention (FDA warning) and sexual dysfunction — that urologists must actively recognize.[1][2][3]

For class-comparison context see Tricyclic antidepressants and Gabapentinoids. For the conditions and procedures these agents orbit, see Female SUI, Urethral Bulking Agents, Chronic Pelvic Pain, and IC/PBS.

Mechanism — Modulation of Onuf's Nucleus and the Continence Reflex​

Motor neurons in Onuf's nucleus (sacral spinal cord) control the external urethral sphincter (rhabdosphincter) and carry uniquely dense serotonergic and noradrenergic terminals. Duloxetine raises extracellular 5-HT and NE in the sacral spinal cord and produces three effects relevant to LUT function:[4][5][6][7]

  1. Facilitation of rhabdosphincter contraction during the storage phase — 5-HT and NE amplify the excitatory effect of glutamate on sphincter motor neurons. Critically, glutamate is the on/off switch — so duloxetine enhances sphincter activity during storage with preserved voiding relaxation in experimental models; this does not rule out clinical urinary retention.[4][5]
  2. Suppression of bladder overactivity under irritated conditions — in animal models duloxetine produces dose-dependent increases in bladder capacity (up to 5×) and periurethral sphincter EMG activity (up to 8×), with minimal effect under normal conditions. Capacity effects are mediated through 5-HT receptors; sphincter facilitation involves 5-HT2 and α1-adrenergic mechanisms.[6]
  3. Enhanced active continence reflex — duloxetine increases urethral response amplitude during sneezing and Valsalva leak point pressure without significantly affecting urethral resting tone — i.e., it works on the active continence mechanism rather than passive tone.[4][7]

This is mechanistically distinct from TCAs: SNRIs lack antimuscarinic, antihistaminic, and direct smooth-muscle-relaxant activity, but this does not remove risks of retention, hypertension, falls, sexual dysfunction or serotonergic toxicity.[2][4]

SUI in Women — the principal urologic application​

Yentreve is licensed in Europe for moderate-to-severe SUI in adult women; duloxetine has no US SUI approval. NICE advises against first-line or routine second-line use, but allows a selected second-line trial when a woman prefers medication to surgery or is unsuitable for surgery. EAU likewise gives a weak recommendation for selected women who remain symptomatic after conservative treatment and wish to avoid an invasive intervention. Counsel about adverse effects and discontinuation.[1][47][48][49]

Cochrane review (10 RCTs, n = 3,944)[10]​

  • Subjective cure favored duloxetine (10.8% vs 7.7%; RR 1.42, 95% CI 1.02–1.98; p = 0.04) — small absolute effect (~3%)
  • ~50% reduction in incontinence episode frequency in individual studies
  • QoL improved (pooled WMD 5.26, 95% CI 3.84–6.68); objective pad-test/24-hour pad-weight cure was not established. About one in eight participants stopped duloxetine because of adverse effects

ACP’s older guidance recommended against systemic pharmacologic treatment for female SUI; this differs from the selected-use option in NICE/EAU and should not be represented as proof of no symptom effect.[11]

Licensed SUI dosing (Europe)​

40 mg twice daily is the Yentreve dose. An initial 20 mg twice daily for two weeks can improve tolerability before escalation. Reassess at 2–4 weeks and regularly thereafter; placebo-controlled efficacy beyond three months has not been evaluated. Taper on withdrawal. A 120 mg/day experimental OAB regimen is not the SUI label dose.[47]

Duloxetine + pelvic floor muscle training (PFMT)​

Combination therapy may offer greater symptom improvement than either treatment alone; trial results do not prove that benefit will be additive in every patient.[12][13][14]

TrialComparisonResult
Ghoniem 2005 (RCT, n = 201)Duloxetine + PFMT vs alone vs no treatment[14]Combination superior on IEF, pad use, and I-QoL
DULOXING 2021 (RCT, n = 158)Duloxetine + innovative PFMT vs duloxetine alone[12]IEF reduction 66.7% vs 50.0%; better ICIQ-SF, PGI-I 70.8% vs 65.6%, I-QoL +19.3% vs +6.6% (all p < 0.05)
Svihra 2021QALY analysis[13]Model projected QALYs over estimated remaining life expectancy (17.90 vs 15.03), using short-term utility scores; these were not observed life-years gained

Sexual function​

Despite SNRIs' general association with sexual dysfunction, in 40 women with SUI on duloxetine 40 mg BID the mean FSFI total rose from 19.9 to 25.7 (p < 0.001) — likely an indirect effect of treating the incontinence and any concomitant depression.[15]

Post-Prostatectomy Incontinence​

There is no approved pharmacotherapy for PPUI. Duloxetine is the most-studied agent, used off-label.

Selected RCTs and series​

StudyDesignKey finding
Cornu 2011 (RCT, n = 31)[16]Duloxetine 80 mg/day vs placebo × 3 mo in post-RP SUIIEF reduction −52.2% vs +19.0% (MD 71.2%, p < 0.0001); improvement in selected symptom/QoL measures
Filocamo 2007 (RCT, n = 112)[17]Duloxetine + rehab vs rehab alone × 16 wk post-catheterAt 16 wk, 39 vs 27 patients dry (p = 0.007). Critical caveat: at 20 wk after planned discontinuation, only 23 (duloxetine) vs 38 (rehab-only) were dry (p = 0.008) — duloxetine may mask rather than accelerate recovery
Sanchez-Salas 2024 (RCT, n = 240, 4-arm)[18]PFMT-biofeedback ± duloxetine vs controlAt 6 mo, continence defined as ≤1 security pad: control 96% vs PFMT-biofeedback 90%, duloxetine 73% (p = 0.008), combined 69% (p = 0.003); active treatments had worse QoL
Kang 2023 (retrospective, n = 197)[19]PFME + duloxetine 30 mg vs PFME aloneCombination better at 2 wk (p = 0.019); no difference at 3, 6, 9, or 12 mo
Schlenker 2006 (open-label, n = 20)[20]Duloxetine 80 mg/dayPad use 8.0 → 4.2/day (p < 0.001)
Collado Serra 2011 (open-label, n = 68, established PPUI)[21]Duloxetine in chronic (> 1 yr) PPUIICIQ-SF 13 → 9 (p < 0.001)

Practical interpretation​

Duloxetine may reduce leakage while taken by selected men, but sustained recovery is uncertain and the 240-person trial did not support routine use to accelerate recovery. EAU offers it weakly as an off-label option, with explicit adverse-effect counseling. A trial needs reassessment and a withdrawal plan; it must not delay PFMT or appropriate surgical referral.[50][22]

Mixed Urinary Incontinence​

The dual-mechanism rationale (sphincter facilitation for stress + indirect modulation of bladder overactivity for urge) is theoretically attractive. Two recent retrospective studies of duloxetine + tolterodine for urge-predominant mixed UI:

StudyNotes
Sobay 2025 (n = 106)[23]OABSS 11.08 → 6.95; ICIQ-SF 15.69 → 8.84; pads 3.58 → 0.73/day; capacity 315 → 436 mL (all p < 0.001)
Polat 2026 (n = 115)[24]Significant improvement in OABSS, ICIQ-SF, pad weights, frequency, nocturia, urgency, and IEF at weeks 4 and 12

Both retrospective and uncontrolled — prospective RCTs are needed before this becomes a recommended combination, and these studies do not establish benefit from adding either drug or identify the optimal sequence.

Overactive Bladder​

Steers 2007 RCT[25]​

Duloxetine (80 → 120 mg/day) vs placebo in women with OAB symptoms (n = 306):

  • Significant reductions in voiding episodes / 24h, incontinence episodes / 24h, daytime voiding interval, and I-QoL at both dose levels
  • Urodynamics: no significant change in maximum cystometric capacity or volume threshold for DO — the trial does not establish which mechanism caused symptom changes
  • AEs: nausea (31%), dry mouth (16%), dizziness (14%), constipation (14%), insomnia (13%), fatigue (11%); PVR rose modestly (< 50 mL)

Multiple sclerosis OAB pilot (Di Rezze 2012)[26]​

Crossover trial in MS patients with OAB; significant improvement in OAB-Q with duloxetine vs both baseline and placebo.

Mechanistic preclinical data​

Duloxetine reverses detrusor overactivity and depression-like signs in a corticosterone-treated rat model via central pathways — distinct from solifenacin and mirabegron, which act peripherally. Effects persist 72 h after discontinuation, suggesting neuroplastic changes. These animal findings do not establish a preferred drug for people with OAB and depression; duloxetine is not standard OAB treatment.[27][28] Convergent mouse data show SNRIs improve micturition control across multiple models.[9]

CP/CPPS​

Duloxetine has limited direct study evidence in CP/CPPS. For the distinct IC/BPS phenotype, amitriptyline is an AUA oral option; this is not a class recommendation for SNRIs.[8]

StudyResult
Giannantoni 2014 (RCT, n = 38)[29]Duloxetine 60 mg + tamsulosin + saw palmetto vs tamsulosin + saw palmetto × 16 wk → significant improvement in NIH-CPSI pain, QoL, and total scores (p < 0.05)
Zhang 2017 (150 enrolled, 126 completed; open randomized three-arm study titled observational)[30]Doxazosin + duloxetine vs doxazosin + sertraline vs doxazosin × 6 mo → response 88.6% vs 63.4% vs 56.1%; NIH-CPSI reduction 12.64 vs 7.41 vs 6.12 (p < 0.05)
Cochrane 2019[31]Antidepressants in CP/CPPS — low to very-low quality; AEs common

Duloxetine fits the multimodal UPOINT model (the "P" psychosocial domain or as a pain-modulating add-on), particularly when neuropathic features, anxiety, or depression are present. The open Zhang study cannot establish a general superiority rule for antidepressant selection or prove a noradrenergic mechanism in an individual patient.[30][32]

Chronic pelvic pain in women​

ACOG’s 2020 discussion of SNRIs for a neuropathic component of pelvic pain draws substantially on other pain conditions; direct female CPP efficacy is uncertain. Choose treatment according to diagnosis, comorbidity and tolerability rather than prescribing an indefinite SNRI course for pelvic pain alone.[33][34]

The 2023 Cochrane network meta-analysis (176 studies; 28,664 participants) found the clearest chronic-pain evidence for duloxetine 60 mg/day, mainly in fibromyalgia, neuropathic and musculoskeletal pain. Effects were small to moderate; higher doses generally did not add benefit. The average trial lasted about ten weeks, and long-term efficacy/safety remained uncertain. This is useful extrapolation, not proof of efficacy in female pelvic pain.[51]

Premature Ejaculation​

SSRIs and SNRIs delay ejaculation pharmacologically. Dapoxetine, a short-acting SSRI, is the only serotonergic agent specifically approved (in Europe, not the US) for on-demand PE.[35][36]

Cochrane SSRI evidence (31 RCTs, n = 8,254)[37]​

  • IELT increased by 3.09 minutes vs placebo (95% CI 1.94–4.25)
  • Perception of improvement: 2× more likely (NNT 5)
  • Satisfaction: RR 1.63; perceived control: RR 2.29
  • Paroxetine most effective long-acting SSRI (MD IELT +6.51 min)
  • Discontinuation due to AEs: NNH 33

Venlafaxine for PE — failed RCT​

Safarinejad 2008 (RCT, n = 222): venlafaxine 75 mg XR vs placebo × 12 weeks — no significant difference in IELT (1.7× vs 1.6×), intercourse satisfaction, or weekly coitus episodes. AEs more common with venlafaxine. Conclusion: "venlafaxine is not better than placebo in treatment of PE."[38]

Duloxetine for PE​

The 2022 AUA / SMSNA Disorders of Ejaculation Guideline lists duloxetine 40 mg/day and venlafaxine 75 mg/day as having a "limited evidence base" for PE.[39]

Dapoxetine​

Meta-analysis of 7 RCTs (n = 8,039): both 30 mg and 60 mg significantly improved IELT and PGIC vs placebo; 60 mg more effective but more AEs. A network analysis ranked dapoxetine 30 mg favorably, but indirect rankings do not establish a universally best treatment. Not available in the US.[40][41]

Clinical interpretation​

Among SNRIs, duloxetine has limited evidence; venlafaxine failed in its only placebo-controlled trial. SSRIs (paroxetine for daily, dapoxetine for on-demand) have stronger evidence. SNRIs are not specifically recommended in the AUA guideline.[39][42]

Individual SNRI Profiles​

AgentUrologic roleNotable urologic AEs
DuloxetineFemale SUI (EU-labeled); male SUI off-label; other pelvic uses have limited or uncertain evidenceUrinary hesitation / retention (FDA warning); sexual dysfunction; nausea (~23%)[1][2]
VenlafaxineNegative PE RCT; no established urologic indicationSexual dysfunction (ejaculatory delay, decreased libido, ED); urinary hesitation[38][43]
DesvenlafaxineNo urologic-specific dataSexual dysfunction; orthostatic hypotension in elderly
MilnacipranFibromyalgia (FDA-approved); pharmacovigilance data only in urologyDysuria, urinary retention, testicular pain, ejaculation disorders — FDA warning specifically about higher GU AEs in males with prostatic hypertrophy[44][45]
LevomilnacipranNo urologic-specific data; FAERS disproportional reporting signals; these are not incidence comparisons with milnacipran[44][46]Monitor BP, urinary and sexual adverse effects

Urologic Adverse Effects​

Urinary hesitation and retention​

The duloxetine label warns that new hesitancy may be drug-related; postmarketing retention has sometimes required catheterization or hospitalization.[2]

A systematic review of RCTs found antidepressants overall, not SNRIs alone, were associated with more voiding disorders than placebo (pooled OR 3.30; 95% CI 1.90–5.72; p < 0.001).[3]

Mechanism: SNRIs increase NE at the bladder neck and proximal urethra → increased urethral resistance → therapeutic for SUI but problematic in voiding dysfunction, BPH, or BOO.[8][46]

New hesitancy/retention: assess bladder emptying and other causes, review the suspected drug with its prescriber, and treat acute retention promptly. Dose adjustment or supervised withdrawal may be needed. Tamsulosin benefit is described mainly in cases/review literature; automatically adding it risks a prescribing cascade and orthostasis.[2][46]

The milnacipran label specifically warns that male patients with a history of obstructive uropathy may have higher GU AE rates.[45]

Sexual dysfunction​

All SNRIs carry FDA warnings about sexual dysfunction across sexes — ejaculatory delay or failure, decreased libido, and ED in men; decreased libido and delayed or absent orgasm in women. Inquire about sexual function before starting and periodically during treatment.[2][43][45]

A FAERS pharmacovigilance analysis found levomilnacipran had stronger reporting signals for some urinary/sexual events; spontaneous-report databases cannot establish incidence or comparative causation.[44]

SIADH / hyponatremia​

All SNRIs can cause SIADH-mediated hyponatremia, particularly in older adults and patients on diuretics — relevant for urologic patients on thiazides for stone prevention; alpha-blockers are not a typical cause of SIADH.

Prescribing boundaries and safety​

Use the licensed SUI regimen above where applicable. Male SUI is off-label; mixed-UI combination therapy, high-dose OAB treatment and pelvic-pain regimens are not standardized prescribing pathways. A low-certainty study dose is not a recommended long-term dose.

  • Duloxetine safety: review BP, falls/orthostasis, urinary retention, liver disease/alcohol exposure, renal function, bleeding risk, sodium and serotonergic interactions. Avoid use with chronic liver disease/cirrhosis, substantial alcohol use or GFR below 30 mL/min under the US label. European Yentreve labeling additionally lists hepatic impairment, CrCl below 30, uncontrolled hypertension at initiation, and potent CYP1A2 inhibitors such as ciprofloxacin/fluvoxamine as contraindications.[2][47]
  • MAOI switching: duloxetine requires at least 14 days after stopping an MAOI, and at least 5 days after stopping duloxetine before starting a psychiatric MAOI. Linezolid/IV methylene blue need the label’s urgent-treatment protocol.[2]
  • Other SNRIs: venlafaxine can raise BP and requires renal adjustment. Milnacipran needs dose reduction for severe renal impairment and is not recommended in ESRD, rather than labeled as contraindicated for ESRD.[43][45]
  • Mood and withdrawal: monitor suicidality and activation; SNRI labels carry the antidepressant suicidality boxed warning. Taper instead of abrupt discontinuation. Sexual adverse effects should be discussed before treatment and reassessed.[2][43][45]

Alpha-blockers and duloxetine act in opposing directions on outlet resistance; combining them does not guarantee normal emptying and may increase orthostatic symptoms. Avoid treating suspected drug-induced retention by reflexively adding another medicine.[2][46]

See Also​

References​

1. Wu JM. "Stress incontinence in women." N Engl J Med. 2021;384(25):2428–2436. doi:10.1056/NEJMcp1914037

2. Eli Lilly. CYMBALTA (duloxetine): prescribing information. Revised July 2025. DailyMed.

3. Trinchieri M, Perletti G, Magri V, et al. "Urinary side effects of psychotropic drugs: a systematic review and metanalysis." Neurourol Urodyn. 2021;40(6):1333–1348. doi:10.1002/nau.24695

4. Schuessler B. "What do we know about duloxetine's mode of action? Evidence from animals to humans." BJOG. 2006;113(Suppl 1):5–9. doi:10.1111/j.1471-0528.2006.00877.x

5. Thor KB. "Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence." Urology. 2003;62(4 Suppl 1):3–9. doi:10.1016/s0090-4295(03)00754-4

6. Thor KB, Katofiasc MA. "Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat." J Pharmacol Exp Ther. 1995;274(2):1014–1024.

7. Miyazato M, Kitta T, Kaiho Y, et al. "Effects of duloxetine on urethral continence reflex and bladder activity in rats with cerebral infarction." J Urol. 2015;194(3):842–847. doi:10.1016/j.juro.2015.03.091

8. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

9. Redaelli M, Ricatti MJ, Simonetto M, et al. "Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice." PLoS One. 2015;10(3):e0121883. doi:10.1371/journal.pone.0121883

10. Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. "Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults." Cochrane Database Syst Rev. 2005;(3):CD004742. doi:10.1002/14651858.CD004742.pub2

11. Qaseem A, Dallas P, Forciea MA, et al. "Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians." Ann Intern Med. 2014;161(6):429–440. doi:10.7326/M13-2410

12. Hagovska M, Svihra J, Breza J, Dubravicky J, Vargovcak M. "A randomized, intervention parallel multicentre study to evaluate duloxetine and innovative pelvic floor muscle training in women with uncomplicated stress urinary incontinence — the DULOXING study." Int Urogynecol J. 2021;32(1):193–201. doi:10.1007/s00192-020-04516-w

13. Svihra J, Hagovska M, Breza J, et al. "Impact of innovative pelvic floor muscle training on quality-adjusted life years (QALYs) in women with stress urinary incontinence treated by duloxetine." Eur J Obstet Gynecol Reprod Biol. 2021;264:25–30. doi:10.1016/j.ejogrb.2021.06.025

14. Ghoniem GM, Van Leeuwen JS, Elser DM, et al. "A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence." J Urol. 2005;173(5):1647–1653. doi:10.1097/01.ju.0000154167.90600.c6

15. Biyikoglu M, Kettas E, Sesli M, et al. "The effect of duloxetine on female sexual functions in the treatment of stress incontinence." Arch Gynecol Obstet. 2023;308(3):1037–1042. doi:10.1007/s00404-023-07123-4

16. Cornu JN, Merlet B, Ciofu C, et al. "Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial." Eur Urol. 2011;59(1):148–154. doi:10.1016/j.eururo.2010.10.031

17. Filocamo MT, Li Marzi V, Del Popolo G, et al. "Pharmacologic treatment in postprostatectomy stress urinary incontinence." Eur Urol. 2007;51(6):1559–1564. doi:10.1016/j.eururo.2006.08.005

18. Sanchez-Salas R, Tourinho-Barbosa R, Sivaraman A, et al. "Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: a randomized clinical trial." Prostate. 2024;84(2):158–165. doi:10.1002/pros.24634

19. Kang CS, Kim DH, Choi JH, et al. "Pelvic floor muscle exercise with or without duloxetine for postprostatectomy urinary incontinence: a retrospective single-center study." Medicine (Baltimore). 2023;102(32):e34657. doi:10.1097/MD.0000000000034657

20. Schlenker B, Gratzke C, Reich O, et al. "Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy." Eur Urol. 2006;49(6):1075–1078. doi:10.1016/j.eururo.2006.01.038

21. Collado Serra A, Rubio-Briones J, Puyol Payás M, et al. "Postprostatectomy established stress urinary incontinence treated with duloxetine." Urology. 2011;78(2):261–266. doi:10.1016/j.urology.2011.03.006

22. Castellan P, Ferretti S, Litterio G, Marchioni M, Schips L. "Management of urinary incontinence following radical prostatectomy: challenges and solutions." Ther Clin Risk Manag. 2023;19:43–56. doi:10.2147/TCRM.S283305

23. Sobay R, Küçük EV. "An investigation of the effect of combining tolterodine and duloxetine in the treatment of mixed-type urinary incontinence and the factors affecting success." J Clin Med. 2025;14(10):3575. doi:10.3390/jcm14103575

24. Polat H, Ekşi M, Çatık A, et al. "Clinical outcomes and safety of duloxetine and tolterodine combination in the treatment of mixed-type urinary incontinence: a single-arm retrospective study." J Int Med Res. 2026;54(3):3000605261430142. doi:10.1177/03000605261430142

25. Steers WD, Herschorn S, Kreder KJ, et al. "Duloxetine compared with placebo for treating women with symptoms of overactive bladder." BJU Int. 2007;100(2):337–345. doi:10.1111/j.1464-410X.2007.06980.x

26. Di Rezze S, Frasca V, Inghilleri M, et al. "Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study." Clin Neuropharmacol. 2012;35(5):231–234. doi:10.1097/WNF.0b013e3182613dce

27. Wróbel A, Serefko A, Woźniak A, et al. "Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways." Pharmacol Biochem Behav. 2020;189:172842. doi:10.1016/j.pbb.2019.172842

28. Finnerup NB. "Nonnarcotic methods of pain management." N Engl J Med. 2019;380(25):2440–2448. doi:10.1056/NEJMra1807061

29. Giannantoni A, Porena M, Gubbiotti M, Maddonni S, Di Stasi SM. "The efficacy and safety of duloxetine in a multidrug regimen for chronic prostatitis/chronic pelvic pain syndrome." Urology. 2014;83(2):400–405. doi:10.1016/j.urology.2013.09.024

30. Zhang M, Li H, Ji Z, Dong D, Yan S. "Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: an observational study." Medicine (Baltimore). 2017;96(10):e6243. doi:10.1097/MD.0000000000006243

31. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

32. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. "Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome." Drugs Aging. 2021;38(10):845–886. doi:10.1007/s40266-021-00890-2

33. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

34. Lamvu G, Carrillo J, Ouyang C, Rapkin A. "Chronic pelvic pain in women: a review." JAMA. 2021;325(23):2381–2391. doi:10.1001/jama.2021.2631

35. Sunder M. "SSRIs and SNRIs for premature ejaculation in adult men." Am Fam Physician. 2022;105(6):591–592.

36. Hoy SM, Scott LJ. "Dapoxetine: in premature ejaculation." Drugs. 2010;70(11):1433–1443. doi:10.2165/11204750-000000000-00000

37. Sathianathen NJ, Hwang EC, Mian R, et al. "Selective serotonin re-uptake inhibitors for premature ejaculation in adult men." Cochrane Database Syst Rev. 2021;3:CD012799. doi:10.1002/14651858.CD012799.pub2

38. Safarinejad MR. "Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study." Andrologia. 2008;40(1):49–55. doi:10.1111/j.1439-0272.2008.00813.x

39. Shindel AW, Althof SE, Carrier S, et al. "Disorders of ejaculation: an AUA/SMSNA guideline." J Urol. 2022;207(3):504–512. doi:10.1097/JU.0000000000002392

40. De Hong C, Ren LL, Yu H, Qiang W. "The role of dapoxetine hydrochloride on-demand for the treatment of men with premature ejaculation." Sci Rep. 2014;4:7269. doi:10.1038/srep07269

41. Sridharan K, Sivaramakrishnan G, Sequeira RP, Al-Khaja KA. "Pharmacological interventions for premature ejaculation: a mixed-treatment comparison network meta-analysis of randomized clinical trials." Int J Impot Res. 2018;30(5):215–223. doi:10.1038/s41443-018-0030-x

42. Gul M, Bocu K, Serefoglu EC. "Current and emerging treatment options for premature ejaculation." Nat Rev Urol. 2022;19(11):659–680. doi:10.1038/s41585-022-00639-5

43. Pfizer. EFFEXOR XR (venlafaxine): prescribing information. DailyMed. Accessed September 12, 2026.

44. Huang T, Zhang P, Zhou Y, et al. "Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA Adverse Event Reporting System." Front Pharmacol. 2025;16:1719881. doi:10.3389/fphar.2025.1719881

45. SAVELLA (milnacipran): prescribing information. Revised September 2025. DailyMed.

46. Asnis GM, Caneva E, Henderson MA. "A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations." Expert Opin Drug Saf. 2016;15(5):717–725. doi:10.1517/14740338.2016.1164138

47. European Medicines Agency. Yentreve (duloxetine): product information. Current SmPC. Accessed September 12, 2026.

48. NICE. Urinary incontinence and pelvic organ prolapse in women (NG123). Recommendation 1.4.35. Guideline.

49. European Association of Urology. Non-neurogenic Female LUTS. 2026. Duloxetine section. Guideline.

50. European Association of Urology. Non-neurogenic Male LUTS. 2026. Drugs for stress urinary incontinence. Guideline.

51. Birkinshaw H, Friedrich CM, Cole P, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023;5:CD014682. doi:10.1002/14651858.CD014682.pub2.